Ahricetamol vs Jin | 93–71 | 56.71% |
Ahricetamol vs Kazuya | 95–65 | 59.38% |
Ahricetamol vs King | 68–72 | 48.57% |
Ahricetamol vs Bryan | 75–47 | 61.48% |
Ahricetamol vs Hwoarang | 56–62 | 47.46% |
Ahricetamol vs Dragunov | 55–56 | 49.55% |
Ahricetamol vs Lee | 59–49 | 54.63% |
Ahricetamol vs Yoshimitsu | 49–54 | 47.57% |
Ahricetamol vs Devil Jin | 55–40 | 57.89% |
Ahricetamol vs Reina | 42–52 | 44.68% |
Ahricetamol vs Steve | 63–26 | 70.79% |
Ahricetamol vs Paul | 39–43 | 47.56% |
Ahricetamol vs Law | 44–35 | 55.70% |
Ahricetamol vs Lili | 37–36 | 50.68% |
Ahricetamol vs Lars | 44–28 | 61.11% |
Ahricetamol vs Asuka | 32–38 | 45.71% |
Ahricetamol vs Feng | 21–46 | 31.34% |
Ahricetamol vs Claudio | 24–36 | 40.00% |
Ahricetamol vs Jun | 37–21 | 63.79% |
Ahricetamol vs Victor | 25–32 | 43.86% |
Ahricetamol vs Alisa | 27–25 | 51.92% |
Ahricetamol vs Xiaoyu | 16–33 | 32.65% |
Ahricetamol vs Lidia | 17–32 | 34.69% |
Ahricetamol vs Azucena | 19–27 | 41.30% |
Ahricetamol vs Nina | 23–19 | 54.76% |
Ahricetamol vs Kuma | 14–28 | 33.33% |
Ahricetamol vs Raven | 21–21 | 50.00% |
Ahricetamol vs Eddy | 15–26 | 36.59% |
Ahricetamol vs Leroy | 16–23 | 41.03% |
Ahricetamol vs Jack-8 | 22–16 | 57.89% |
Ahricetamol vs Shaheen | 12–18 | 40.00% |
Ahricetamol vs Leo | 14–14 | 50.00% |
Ahricetamol vs Zafina | 11–14 | 44.00% |
Ahricetamol vs Panda | 7–5 | 58.33% |
Limitations
This data is often requested to give insight into which characters you have more trouble with than others, but it is not particularly helpful for that. The main issue is that it is heavily skewed by how strong the opponents you play are.
For example, this data suggests my worst matchup is clearly vs Reina, but that's just because most of those games are vs Yagami.
There is a way to account for this being worked on. The central idea is to assign each matchup a rating vs you which adjusts based on the result, much like the regular rating but also based on the rating of each player. With this, it would give a better summary of how well you perform vs each character.
In the meantime, this page is here to present the data as requested.